Advertisement

Topics

Cypralis and Gilead Sciences, Inc. agree on license terms under which Cypralis will hold exclusive development and commercialization rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseases

02:00 EST 8 Jan 2018 | Sciad Newswire

Original Article: Cypralis and Gilead Sciences, Inc. agree on license terms under which Cypralis will hold exclusive development and commercialization rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseases

NEXT ARTICLE

More From BioPortfolio on "Cypralis and Gilead Sciences, Inc. agree on license terms under which Cypralis will hold exclusive development and commercialization rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...